Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.59 |
| ▸ | TNKS | O95271 | 5/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.59 |
| ▸ | HTR2A | P28223 | 5/20 | 0.56 |
| ▸ | HTR2C | P28335 | 4/20 | 0.56 |
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
| ▸ | HTR6 | P50406 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9009907 | 0.94 | PARP1 (0.67) | PARP1TNKSTNKS2HTR2AHTR7 | |
| SCHEMBL6795915 | 0.87 | PARP1 (0.70) | PARP1TNKSTNKS2HTR7HTR1A | |
| SCHEMBL9010001 | 0.87 | PARP1 (0.57) | PARP1HTR2AHTR2CDRD2MEN1 | |
| SCHEMBL16432166 | 0.85 | PARP1 (0.69) | PARP1TNKSTNKS2MEN1KMT2A | |
| SCHEMBL14129617 | 0.85 | PARP1 (0.64) | PARP1TNKSTNKS2HTR7HTR1A | |
| SCHEMBL14264637 | 0.84 | HTR2A (0.54) | PARP1HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL18934376 | 0.79 | PARP1 (0.50) | PARP1TNKSTNKS2HTR2AHTR2C | |
| SCHEMBL1582470 | 0.77 | HTR2A (0.87) | HTR2AHTR2CHTR7HTR6CYP1A2 | |
| SCHEMBL16432069 | 0.77 | PARP1 (0.70) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL18729762 | 0.77 | PARP1 (0.61) | PARP1TNKSTNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188103-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-29 | — | — | US | disclosed |
| US-8188103-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-29 | — | — | US | disclosed |
| US-20110077245-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | VAN DER AA MARCEL JOZEF MARIA | 2011-03-31 | — | — | US | disclosed |
| US-20110077245-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | VAN DER AA MARCEL JOZEF MARIA | 2011-03-31 | — | — | US | disclosed |
| US-7875621-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-25 | — | — | US | disclosed |
| US-7875621-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-25 | — | — | US | disclosed |
| US-20080176876-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | JANSSEN PHARMACEUTICA, NV (BE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176876-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | JANSSEN PHARMACEUTICA, NV (BE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176876-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | PARP1, PARP2, PARP3 | PARP1 1/4885TNKS 18/4885TNKS2 66/4885 |
| US-20110077245-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885TNKS 14/4885TNKS2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.